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Advisor: Professor Herb Karpatkin 
Background: Persons with MS (pwMS) are limited in their mobility due to thermosensitivity. 
Exercising at a sufficient volume and intensity to increase mobility can result in increased core 
temperatures and resultant worsening of symptoms. The use of cooling garments to lower core 
temperature has been found to be a successful means of allowing pwMS to exercise for longer 
periods. Previous studies have relied on precooling for an extended period of time prior to 
activity, to achieve improved exercise performance. Cooling during the performance itself, or 
pericooling, may allow for similar performance gains to be realized without spending the time 
needed for precooling.  
Objectives: The purpose of this study is to examine the effects of pericooling on the Six Minute 
Walk Test (6MWT) performance in pwMS. It was hypothesized that pwMS would have better 
6MWT performance while wearing a cooling vest then compared to a noncooled condition. If 
our hypothesis were correct, it would suggest that pwMS could achieve improved exercise 
performance without engaging in precooling activities. 
Methods: A randomized crossover design was used. Patients were randomized into cooled or 
uncooled conditions. Cooled subjects would perform a 6MWT, donning a commercially 
available cooling vest immediately prior to the walk. Walks would be performed once a week for 
three weeks. Total 6MWT distance and minute-by-minute distance was recorded. Fatigue during 
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the walk was measured using the Visual Analog Scale of Fatigue. Uncooled subjects would 
perform the identical protocol without a cooling device.  Following the three walks in one 
condition, subjects would undergo a two-week washout period and then repeat the same protocol 
in whatever condition they did not experience initially. 
Results: Six females with mild MS (EDSS 2.67) completed the study. Pericooling resulted in 
walking significantly, (F (1,17) = 4.63, p = .046, partial η
2
 = .214) farther in the cooled condition 
(1257’) than in the uncooled condition (1154’). There was no significant difference in VAFS 
scores between the 2 conditions. 
Conclusions: Pericooling, delivered via a commercially available cooling vest resulted in better 
6MWT scores than an uncooled condition in pwMS. As most studies of cooling in MS utilize 
cooling prior to an activity, these results indicate an alternative and less time consuming means 
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Multiple Sclerosis (MS) is a chronic neurological disease, which involves inflammation, 
axonal demyelination, and oxidative stress (Romme Christensen et al., 2013) in the central 
nervous system that can be relapsing and remitting or progressive (Frohman, Davis, & Frohman, 
2011).  While the etiology of the demyelinating lesions is unclear, these lesions have been shown 
to be in both gray and white matter and are the primary cause of neurological and physical 
symptoms (Lucchinetti et al., 2011).   
Research suggests that demyelinating lesions result in scar tissue, which leads to changes 
in axonal physiology, loss of saltatory properties of electrical conduction, reduction in 
conduction velocity, and a predisposition to conduction block (Frohman et al., 2011).   This can 
be especially disruptive to the propagation of action potentials, which need to travel across 
myelin sheath gaps known as nodes of Ranvier.  Nodes of Ranvier in healthy myelinated axons 
are typically about one micrometer in length.  The physiology of the myelinated axons allows for 
a current that is between three and seven times greater than necessary to produce an action 
potential.  This excess is known as the safety factor (Smith & McDonald, 1999).  However, 
demyelinated axons have a much lower safety factor, which can be less than the current 
itself.  This decrease in the safety factor occurs because the current is no longer insulated by the 
myelin sheath, which propels the current from one node to the next.  The current is therefore 
improperly directed along the axolemma and is dispersed, resulting in decreased conduction of 
current to the next node.  In addition, the widening of the nodes results in an increase in electrical 
capacitance, further reducing the safety factor.  As long as the safety factor is greater than one, 
conduction will continue to occur, albeit at a slower rate than typical.  Cases in which the safety 
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factor is below one result in the failure of the conduction of the action potential from one node to 
the next and can ultimately lead to a conduction block.  In the event of a conduction block, the 
individual will exhibit more severe symptoms, which are determined by the location of 
demyelination. This demyelination can occur anywhere in the CNS for example, if the motor 
neurons are affected, individuals will present with paralysis, and if the optic nerves are affected, 
individuals will present with blindness (Smith, 1994). 
While pwMS exhibit a variety of physical, cognitive, and neurological symptoms, the 
most commonly experienced symptom is fatigue (Karpatkin, 2005).  Fatigue can be primary or 
secondary in nature.  Primary fatigue is directly caused by the disease and can be the result of 
axonal demyelination, inflammation, and degeneration of axons.  Secondary fatigue is indirectly 
caused by the disease and can be a result of sleep deprivation, pharmacological treatments, and 
muscle disuse (Braley & Chervin 2010).  Psychological factors also play a role in an individual’s 
perception of fatigue (Kos, Kerckhofs, Nagels, D'Hooghe, & Ilsroukx, 2008).   
Researchers have found that the clinical signs that accompany demyelination are 
worsened by an increase in body temperature (Davis, Wilson, White, & Frohman, 2010).  Davis 
et al. suggests that an increase in body temperature affects the propagation of action potential and 
the refractory period, and further contributes to conduction blocks.  Primarily, an increase in 
temperature shortens the action potential duration, thereby decreasing the amount of time for 
depolarization of the demyelinated axolemma to its firing threshold.  A temperature increase, in 
conjunction with a decreased safety factor, increases the likelihood of a conduction block (Smith, 
1994).   
Heat exposure can have rapid effects on both physical and cognitive functions.  It can 
cause increased fatigue, decreased muscle strength, gait difficulties and an inability to think 
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clearly (Geisler et al., 1996).  Heat-induced exacerbations are found in approximately 60-80% of 
MS patients and are usually reversible when the source of heat is removed (Davis et al., 2010).  
Many individuals with MS are extremely sensitive to even small changes in temperature such 
that exposure to the sun can cause an individual with a limping gait to be unable to walk, and a 
hair dryer can exhaust an individual of energy entirely (Baker, 2002).  Heat can have such severe 
implications that one may need to be supported in a warm bath in order to prevent drowning 
(Smith, 1994).   
The effects of heat exposure in individuals with MS are exacerbated by deficits in neural 
control of homeostatic body temperature, which impacts both autonomic and endocrine 
thermoregulation by diminishing hypothalamic thermal response and sweat gland function 
(Davis et al., 2010).  Sweating, one of the primary heat dissipation mechanisms in the body is 
paramount in maintaining internal temperature.  Several studies have reported diminished 
sweating responses in individuals with MS.  Some studies tested subjects using quinizarin 
powder, a gray substance that changes its shade to blue when exposed to sweat.  Others delivered 
a cholinergic agonist transdermally that stimulated eccrine sweat glands without the involvement 
of the CNS.  In addition, to ensure that thermoregulatory effector responses were being 
sufficiently engaged, another study utilized a whole body heating tube-lined suit as opposed to a 
locally induced agonist.  Decreased sweat gland output was observed in all of the experiments, 
suggesting that CNS lesions or impairments in neural control of sudomotor pathway could 
contribute to reduced sweat function in individuals with MS (Davis et al., 2010). 
Because exercise increases core body temperature, it can also result in heat exacerbations 
for pwMS, and those with thermosensitivity can be less inclined to exercise.  Fjelstad, Brittain, 
Fjelstad, and Pardo (2010) studied the relationship between thermosensitivity and physical 
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activity in 77 pwMS.  Subjects indicated their level of physical activity through questionnaires, 
and self-reported the presence or absence of temperature-induced symptoms.  Those with self-
reported thermosensitivity relayed considerably lower levels of physical activity than those 
without (p<0.05).  This demonstrates that thermosensitivity can be responsible for reduced 
physical activity in pwMS. 
Exercise, however, is extremely beneficial for pwMS, and various studies have 
demonstrated the value of aerobic training for pwMS.  In a study done by Petejan et al. (1996), 
after a 15-week aerobic training program subjects demonstrated gains in maximum oxygen 
consumption (VO2 max) and upper and lower extremity strength and decreases in skinfolds, 
triglycerides, LDL’s, depression, and fatigue, suggesting that individuals with MS generate the 
same responses to exercise as those without MS.  In a longer study conducted by Rodgers and 
Mulcare (1999) that coursed the span of six months, improvements were seen in VO2max, 
whereas in a shorter study conducted by Mostert and Kesselring (2002) that coursed the span of 
four weeks, improvements were not seen with VO2max.  This suggests that the length of training 
might be a factor in improving this parameter.    
Resistance training has also been shown to be efficacious.  An eight-week lower 
extremity resistance training study conducted by Harvey, Smith, and Jones (1999) revealed 
improvement in chair transfer time.  In addition, a three-month progressive resistive exercise 
program study conducted by Kraft et al.  (1996) showed improvement in functional tasks, such 
as stair climbing and ambulation and increased muscle strength of the trained limbs (as cited in 
Dalgas, Stenager, & Ingermann-Hansen, 2008). 
Romberg et al. (2004) studied 95 pwMS to evaluate the effect of a six month combined 
resistance and aerobic exercise program on walking speed (median EDSS: 6 for experimental 
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group and 5.5 for control group).  Patients in the experimental group were given an inpatient 
exercise routine during the first three weeks and then proceeded to complete a progressive home 
exercise program consisting of three strength training, and one aerobic routine each week from 
weeks 4-20.  One strength training routine was added for weeks 21-26.   Patients kept a diary to 
record adherence to these routines.  Patients in the control group were asked to refrain from 
making any major changes in their level of physical activity during these six months.  Walking 
speed was assessed by measuring the time it took for subjects to perform the 25 Foot Walk Test 
(25FWT) and 500 meter walk test (500MWT) at maximum speed.  Walk time was significantly 
decreased in both tests in the experimental group after the six months of exercise.  Though 
25FWT time also decreased in the control group, the change was much greater in the 
experimental group.  No change was observed in 500MWT time in the control group.  This study 
illustrates that exercise can significantly improve the walking speed in pwMS. 
Exercise has various other benefits in addition to its physical implications.  It can provide 
significant psychological benefits for pwMS by giving them a feeling of control over their lives 
(Johnson, 1996).  Studies have shown that exercise can reduce the depression and anxiety 
experienced by pwMS (Turner 2009).  Exercise can also reduce secondary fatigue caused by 
disuse (Karpatkin, 2005).  However, pwMS may be prevented from reaping the benefits of 
exercise due to their sensitivity to temperature elevation.    
Cooling prior to exercise, also known as precooling, has been suggested as a means of 
reducing this temperature elevation and allowing pwMS to exercise with fewer heat induced 
symptoms.  Cooling methods include drinking cold beverages, immersing one’s limbs in cold 
water and wearing cooling garments (White, Wilson, Davis, & Petajan, 2000).  Ku, 
Montgomery, Lee, Luna, and Webbon (1999) differentiate between cooling garments that use 
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active and passive cooling.  In an active cooling garment, such a liquid cooling garment, a liquid 
coolant is circulated through the garment and then to a portable chiller or heat exchange unit 
where it is cooled down again.  In a passive cooling garment the temperature depression is 
accomplished through ice packs in the pockets of the garment or the use of evaporative 
cooling.  Active cooling garments provide better temperature control and have been shown to be 
a more effective means of cooling.   However, passive cooling garments tend to be lighter, more 
portable, easier to use, and less expensive than active cooling garments (Meyer-Heim et al. 
2007).      
In fact, cooling has been found to increase exercise endurance even in the general 
population.  Tyler and Sunderland (2011) performed a crossover study to explore the effect of 
cooling via a cooling collar on the perceived level of thermal strain.  They found that wearing the 
cooling collar increased the time taken to reach volitional exhaustion and that the subjects in the 
cooled condition could exercise longer before reaching identical levels of perceived exertion 
despite having higher rectal temperatures and heart rates at this point.  This study suggests that 
the experience of feeling cool allows individuals to exercise longer despite higher body 
temperature. 
Subjective measures have been used to explore the effects of precooling on performance 
in pwMS.  Flensner and Lindencrona (1999) studied the effects of a cooling suit on the self-care 
ability of MS patients.  The quasi-experimental before-and-after single case study included ten 
persons in variable stages of MS, who were instructed to wear a cooling cap and waist coat daily 
for a period of at least four weeks.  Data were collected using the MS Self-Care Activities of 
Daily Living (ADL) Scale, open-ended interviews before and after the intervention, and daily 
diaries.  Six out of ten subjects reported marked improvements in their ability to walk indoors 
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and outdoors and five out of ten reported significantly increased ability to move and transfer.  
Additionally, five out of ten reported increased strength and energy in the performance of 
activity.  Flessner and Lindencrona (2002) studied 8 people in various stages of MS to determine 
if the use of a cooling suit influenced their experience with fatigue in daily life.  They used a 
single case-control design approach in which the subjects were instructed to wear a cooling head 
cap and waist coat for several sessions daily for at least four weeks.  The outcomes were 
measured through self-assessment using the Fatigue Impact Scale, open-ended interviews before 
and after the intervention, and daily diaries.  Seven out of eight subjects reported decreased 
levels of muscular fatigue, and six out of eight reported that it was easier to participate in social 
activities.  Although subjective measures are valuable in reflecting a patient’s perception of 
fatigue, more objective measures are necessary to quantify the actual benefits of cooling. 
Several studies have used objective measures to determine the efficacy of using 
precooling to diminish various MS symptoms.  Feys et al. (2005) studied the effect of cooling on 
intention tremors in 18 pwMS (Mean Expanded Disability Status Scale (EDSS of 5.8) who 
exhibited an intention tremor in at least one upper limb.  The subjects' forearms were cooled 
down using a cryomanchet with cold liquid circulating inside to keep skin temperature 
constant.  In one group, the skin was cooled down to 18 degrees Centigrade (the deep cooling 
group), and in another, it was cooled to 25 degrees Centigrade (the moderate cooling group).  
Intention tremor was measured using a wrist step-tracking device, which measured wrist flexion 
and extension as the subjects performed a directed task-the step tracking task and the finger-to-
nose test.  Assessments were made prior to cooling, immediately post-cooling, and after 10, 20, 
and 30 minutes had elapsed.  The subjects in the deep cooling group did worse on the finger 
tapping task right after cooling, but their performance returned to normal after ten minutes 
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(p<.001).  Their speed also decreased in the step tracking task, though it improved over the next 
30 minutes of evaluation (p<.0001).  The accuracy of this task increased initially but returned to 
normal after ten minutes (p<.001).  Both the path length and the number of changes in direction 
(both of which were indicators of tremor) were significantly decreased in this group (p<.0001 for 
both).  The moderate cooling condition did not exhibit any significant changes in the finger 
tapping test or in the performance of the step tracking task.  However, subjects demonstrated 
significantly reduced tremor amplitude immediately after cooling (p<.05) as well as reduced 
tremor frequency.  These changes lasted throughout the three minutes of evaluation after 
cooling.   This study indicates that cooling can significantly decrease intention tremor in pwMS. 
Schwid et al. (2003) performed a randomized crossover study to determine the acute and 
chronic effects of a cooling suit on pwMS.  Seventy-five pwMS (mean EDSS of 3.3) and heat 
sensitivity participated in this experiment.  To test the acute effects of cooling, patients were 
randomly assigned to either low dose (75 degrees Fahrenheit) or high dose (55 degrees 
Fahrenheit) cooling.  After ten minutes of rest, patients wore the appropriate cooling garment for 
60 minutes and then rested again for 30 minutes without the garment.  Neurological assessments 
were performed before cooling and after the 30-minute rest using the MS Functional Composite 
(MSFC).  To assess the chronic effects of cooling, half of the subjects were instructed to wear 
the cooling garments, which were set at a high dose temperature, at home one hour a day for four 
weeks.  The remaining subjects wore no cooling garment and were simply 
observed.   Neurological assessments were performed before the cooling and then again at the 
end of four weeks after a high dosed cooling period identical to the one performed in the acute 
phase of the experiment.  Subjects also filled out daily self-evaluation measures of fatigue and 
neurological function using the Modified Fatigue Impact Scale (MFIS) and the Rochester 
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Fatigue Diary (RFD) and by rating energy level, muscle strength and cognitive function on a 
nine-point Likert Scale.  The groups were reversed after a one-week washout period, and the 
tests were repeated.  In the acute phase of the experiment, a small improvement in the MSFC 
was shown in the high dose cooling group (p=.0073) while the low dose group only exhibited a 
trend toward improving (p=.087).   In the chronic phase, subjects whom had been cooled for one 
hour each day for a month improved on the MSFC after the acute cooling session (p=.041) while 
those patients in the observational group showed no significant changes (p=.21).  Patients 
reported less fatigue on both the MFIS and the RFD (p<.001 for both) during the month of 
cooling.   Additionally, 75.3% of patients reported having more energy during the cooling month 
as compared to 39.4% of the observational group (p<.0001), 57.8% of the cooled group reported 
increased strength during this month as compared to 30.9% in the observational group, and 
55.0% of the cooled patients reported cognitive improvements compared to 30.7% in the 
observational month (p<.0001 for all three measures).  This experiment shows that cooling can 
be a useful way to decrease various symptoms of MS. 
Syndulko, Woldanski, Baumhefner, and Tourtellotte (1995) performed two pilot 
experiments, which studied the immediate and cumulative effects of cooling on functional 
impairments due to MS.  Nine heat-sensitive individuals with MS participated in the first 
experiment, which studied the immediate effects of cooling utilizing a single group repeated 
measure design.  The experiment consisted of a screening session comprised of a neurological 
exam and testing sessions.  The testing sessions involved an examination period both before and 
after a resting period, which included a variety of tests for lower extremity speed, standing 
balance, and tandem gait within parallel bars.  On two of the three sessions, the subjects were 
cooled for 90 minutes during the resting period using a different cooling garment on each day.  
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No statistically significant changes of any measures were produced by either of the cooling 
garments, which is in contrast to the results produced by other studies.  These results can 
possibly be attributed to the small temperature changes that these garments produced of -0.6+- 
0.4 degrees Celsius and 0.5+-.25 degrees Celsius as well as the fact that a resting period alone in 
an air-conditioned environment can produce a tympanic temperature drop of up to 0.4 degrees 
Celsius.  This finding may suggest that the non-cooled session was an unfit control for this 
experiment since the air-conditioned environment alone can serve as a beneficial cooling 
device.   
The second experiment performed by Syndulko et al. (1995) studied the cumulative 
effects of cooling on functional impairments due to MS.  Seventeen thermosensitive individuals 
with MS participated in the experiment, which used an unblinded, parallel group design.  The 
participants were initially divided into two groups: a low-high cooling group and a high-high 
cooling group.  The low cooling protocol produced larger temperature drops than expected of up 
to -0.4 C and was therefore an invalid control, and a non-cooled group was later added.  The 
experiment involved a nine-week program.  The first three weeks were baseline testing weeks in 
which the subjects practiced at home walking, maintaining balance, etc.  During the following 
six weeks the subjects utilized one of two cooling protocols in addition to the home practice, and  
subjects in the non-cooled group did the home practice without any cooling protocols.  During 
this six-week period, the subjects in the cooling group were cooled during their weekly 
evaluations while those in the control group were not.  There were statistically significant 
improvements in both standing balance (p=.0091) and tandem gait (p=.0191) due to the 
immediate effects of cooling.  Eight out of 12 subjects reported that the cooling therapy produced 
immediate improvement in function, ambulation, and increased energy lasting up to two to three 
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hours after cooling.  The tandem gait test showed improvement over time (p=.0062) as did lower 
extremity coordination (p=.0302).  This experiment illustrates the positive immediate and 
cumulative effects of cooling, however, it fails to address its effects on more functional gait 
activities.    
Numerous studies have been conducted to specifically assess the effect of precooling on 
ambulation in pwMS.  White et al. (2000) performed a randomized control trial testing the effect 
of precooling on walking performance in six ambulatory individuals with chronic MS (mean 
EDSS score of 3.1±0.9) who had self-reported thermosensitivity and fatigue.  The research 
consisted of two 30-minute sub-maximal exercise sessions (combined arm leg ergometry), one of 
which was preceded by precooling using an emersion bath.  The number of steps and time 
required to walk 25 feet were recorded before, immediately after, and 30 minutes following the 
exercise sessions.  Results showed that the frequency of steps immediately after exercise was 
significantly better for the precooled sample (P<.05).  Though walk time also improved in the 
cooled subjects, these results were of borderline significance (p=.057).  In addition, subjects in 
the precooled group reported fewer heat induced symptoms such as ataxia, blurred vision, foot 
drop and had lower rates of perceived exertion (RPE) during exercise (12 precooled: 14 non 
cooled, P < .05).  Although the small sample size poses a limitation, this study suggests that 
precooling may be a viable method of reducing exercise-induced fatigue in individuals with 
MS.   
Nilsegard, Denison, and Gunnarsson (2006) studied 43 heat-sensitive pwMS (median 
EDSS score of 4.0) to determine the effect of wearing a commercially produced cooling vest on 
various measures of gait.  This study utilized a randomized crossover design, in which subjects 
were tested before and after a 45-minute session of wearing this vest.  The vest was cooled in a 
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freezer at -20 degrees Celsius for one group and was left at 22 degrees Celsius for the other.  The 
primary measures were the ten and 30-meter timed walk, which evaluated the time and mean 
stride length of the subjects walking ten and 30 meters respectively.  Both speed and stride 
length significantly improved in both the ten and 30-meter timed walk tests.  This study 
illustrates that a cooling vest can successfully improve speed of ambulation in pwMS but fails to 
address the effect of precooling on walking endurance.   
Meyer-Heim et al. (2007) examined the short-term effects of pericooling, cooling during 
an exercise activity, using a lightweight cooling-garment technology on the functional abilities of 
20 thermosensitive individuals with MS (EDSS ≤ 6.5) in a single blinded, balanced cross over 
study.  During the assessments, the subjects wore a properly working cooling device on one day 
and inoperable one for sham control on the other.  The study measured walking capacities 
(25FWT), body sway, muscle strength, and spasticity.  The cooling garment was found to 
significantly improve the 25FWT (p=.035), lower limb strength (p=.004 and p=.037), and MS 
functional composite (MSFC) (p=.017).  While, this study examined the effects of pericooling on 
the walking abilities of thermosensitive individuals, it failed to address its effects on longer more 
functional distances. 
Coyle, Krupp, Doscher, Deng and Milazzo (1996) researched the effects of cooling on 
the timed walk, muscle strength, and coordination.  The study utilized a randomized cross over 
trial to examine 11 ambulatory relapsing and remitting thermosensitive MS patients (mean EDSS 
2.7 ± 0.6).  The subjects participated in two 45-minute sessions using a cooling garment. The 
cooling session lowered their core body temperatures by at least 1 degree Celsius, and the sham 
cooling session lowered their core body temperatures by less than 0.5 degrees Celsius.  The 
subjects were evaluated before and after the cooling and sham cooling sessions.  The variables of 
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interest were 25FWT lower extremity strength, and coordination.  After cooling the core body 
temperature of the subjects by at least 1 degree Celsius, significant improvements were noted in 
all evaluated areas.  With the times walk test, 73% of cooled subjects improved by one to ten 
seconds (p=.0010) while the sham cooling subjects exhibited no improvements.   Additionally, in 
the cooled group, muscle strength improved in both upper and lower extremity muscles  
(p=.0010).  The study illustrates the effects of cooling on the ability of thermosensitive 
individuals to walk short distances.   
Grahn, Murray, and Heller (2008) studied the effects of cooling on walking longer 
distances in pwMS.  This study examined the effects of cooling one hand on the physical 
capacity of ten independently ambulating individuals with chronic MS and a history of 
thermosensitivity (midrange EDSS) using randomized paired trials.  A baseline assessment 
examined the subjects’ physical performance on a treadmill and ability to walk long 
distances.  During the subsequent sessions, the treadmill was adjusted to 65% of the maximum 
workload.  The cooling session involved placing one hand in the cooling device (18-21° C) prior 
to the onset of treadmill activity and throughout the exercise.  Mean exercise durations were 
analyzed, and the cooling treatment extended the exercise duration by an average of 35% 
(p<.0003).  This study illustrates that hand cooling can improve the ability of pwMS to walk 
long distances. 
Although the study by Grahn et al. showed positive results, testing ambulation using a 
treadmill is not necessarily generalizable to functional walking since treadmill walking differs 
from over ground walking in many ways.  Because the surface is in motion, some muscles are 
more active than they would be on ground, while others are less active.  Furthermore, on a 
treadmill the surface is constant in contrast to over ground walking in which surfaces 
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vary.  Lastly, on a treadmill, one will maintain a constant speed while with over-ground walking, 
one’s speed will vary with time.  Therefore, the use of a treadmill to measure the effects of 
cooling on gait endurance will not be identical to the effects of cooling on gait endurance in 
functional environments.   
Reynolds, Short, Westwood, and Cheung (2011) looked at the effect of head and neck 
cooling on both short term and long term ambulation in pwMS.  The researchers utilized a 
double blinded crossover design and tested six female MS patients (EDSS range: 2.5-6.5, no 
mean recorded) with heat sensitivity.  Participants were each subjected to the pre-cooling, sham 
cooling, and no cooling conditions on three separate visits.  In the cooled condition, participants 
wore a head and neck cooling device for 60 minutes prior to ambulation testing and then 
performed through the 6MWT, the 25FWT, and the Timed Up and Go Test (TUG).  In the sham 
cooling phase, they wore a similar device before testing that allowed the participants to 
experience the cooling sensation without any significant decrease in body temperature, and in the 
non-cooled condition, they simply rested for 60 minutes prior to testing.  There was a significant 
improvement in the 6MWT seen in the cooled group (p=.036) as compared to the other two 
groups.   TUG scores were better in both the sham and cooled group than the non-cooled group 
(p=.004), and there was no significant difference in the 25FWT (p=.135).  The authors concluded 
that pre-cooling can improve ambulation in pwMS, though the small sample size limits the 
reliability of this study.   
Previous studies have examined the effects of both precooling and pericooling on short 
distance ambulation, however, the effects of cooling on long distance ambulation has not been 
well studied.  While Grahn et al. (2008) studied the effects of pericooling on long distance 
walking, the ambulation measure using a treadmill doesn’t reflect a functional 
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environment.  Reynolds et al. (2011) studied the effects of precooling on long distance 
ambulation using the more functional 6MWT, but further studies are necessary due to the small 
sample size.  Additionally, pericooling may be a more practical form of cooling in the daily life 
of an MS patient because it does not require extensive preparation before each 
activity.   Pericooling may also be a more effective form of cooling due to the constant presence 
of a cooling source throughout activity. 
 
PURPOSE  
Persons with Multiple Sclerosis are known to have difficulty with ambulation 
endurance.  Because thermosensitivity is a prominent feature of MS, elevation of body 
temperature generated by walking can contribute to these limitations.  Cooling has been shown 
to improve short distance walking in pwMS, but its effects on long distances are not well 
studied.  The purpose of our study is to examine the effects of peri-cooling on gait endurance in 
pwMS.  We hypothesize that the use of a cooling garment will significantly improve gait 
endurance.  If our hypothesis is proven correct, cooling during gait can be used to enhance both 
therapeutic and functional environments, maximizing patient performance in activities that 











A sample convenience consisting of 6 subjects were recruited from Herb Karpatkin 
Physical Therapy in New York, NY using flyers detailing the nature of this study (see appendix 
A).  Subjects signed informed consent forms (see appendices B and C), approved by the 
Institutional Review Board at Hunter College.  The inclusion criteria comprised of a definitive 
diagnosis of MS, the ability to ambulate continuously for six minutes with or without a device, 
and the ability to understand and sign an informed consent.  Participants were excluded if they 
had any type of orthopedic or cardiopulmonary condition preventing their ability to walk six 
minutes, were using steroids or had an exacerbation of their MS-specific symptoms immediately 
prior to or during the study. 
 
PROCEDURES 
During the initial session, participants filled out an intake form (see appendix D), detailing 
subject demographics such as MS type, years since diagnosis, age, gender, EDSS level, 
medications, and assistive devices.  They also filled out a Fatigue Severity Scale (FSS) (see 
appendix E) and the Multiple Sclerosis Impact Scale (MSIS-29) (see appendix F).  Subjects were 
randomly assigned into a cooled or uncooled group for the first phase using a lottery system.  
Subjects were tested twice weekly for 3 weeks.  Sessions began with a 15 minute seated rest 
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period, after which subjects were asked to rate their baseline fatigue using the Visual Analogue 
Fatigue Scale (VAFS) (see appendix H).  The testing then comprised of the 6MWT, in which the 
subjects were asked to walk as far as they could at their best comfortable pace in six 
minutes.  All subjects were accompanied by an examiner, who guarded them throughout the 
entirety of the 6MWT.  The distance was measured minute by minute by another examiner who 
followed the subject’s walking path with a measuring wheel.  Fatigue was then assessed after the 
6MWT using the VAFS, and the difference between the fatigue reported before and after the six 
minute walk was recorded.  The members of the cooled group donned a cooling vest 
immediately preceding the 6MWT, which they wore for the duration of the test.  The cooling 
vest was constructed of canvas and held nine ice packs, weighing a total of 4 pounds. The 
members of the uncooled group performed an identical procedure without the cooling 
vest.   After the three measurements were completed, there was a two-week washout period to 
limit the training effects of the testing.  There was then a crossover in which the subjects 









 (3 Sessions) 





 (3 Sessions) 
Once a week for  
3 weeks 
 
Day 1: Demographics, Characteristics, EDSS, FSS, MSIS (n=6) 
Randomized Allocation 
Cooled Group  Uncooled Group 
15 minute rest 
VAFS Prior to 6 MWT  
 
15 minute rest 
VAFS prior to 6 MWT 
Sessions 4-6: 6 MWT with 
 Cooling vest   
 
No data collected 
(No exercise performed) 
No data collected 
(No exercise performed) 
Post 6MWT VAFS Post 6MWT VAFS 
Uncooled group 
Sessions 4-6: 6 MWT without 
 Cooling vest   
 
Sessions 1-3: 6 MWT without 
cooling vest 
    Groups Cross Over 
Sessions 1-3:6 MWT with 
 Cooling vest   
Cooled group 
Post 6MWT VAFS Post 6MWT VAFS 
 
Figure 1: Methodology Flow Chart 
EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; VAFS, Visual Analogue Fatigue Scale; MSIS, Multiple Sclerosis 
Impact Scale; 6MWT, 6 Minute Walk Test; 
 
15 minute rest 
VAFS Prior to 6 MWT  
 
15 minute rest 





 The purpose of this study was to examine differences between exercise conditions (i.e., 
cooled versus uncooled) with regard to fatigue, length of walking time (in minutes), and the 
percentage difference in walking time (in minutes) with a sample of six adult females diagnosed 
with MS.  The mean age of the six participants was 51.33 years (SD = 2.87), and ages ranged 
from 32 to 69 years.  The mean length of years since diagnosis was 20.50 years (SD = 2.53) with 
length of years since diagnosis ranging from four to 35 years.   
 To determine if significant differences emerged across conditions with regard to the three 
variables of fatigue, walking time, and percentage difference in walking time, a repeated-
measures multivariate analysis of variance (MANOVA) was conducted.  Due to the small sample 
size, bootstrapping (using a replication sample of 1000) was employed. Bootstrapping is a 
relatively common statistical procedure in MS studies, including clinical trials, with small 
samples (see Humphreys, Drummond, Phillips, & Lincoln, 2013; Palacios, Alonso, Bronnum-
Hansen, & Ascherio, 2011; Saxton et al., 2013).  
Because the repeated-measures MANOVA involved just two levels of repeated measures, 
the assumption of sphericity was not relevant to this analysis.  Results from the repeated-
measures MANOVA showed a trend toward significance: Wilks λ (3,15) =  0.65, F(3,15) = 2.65, 
p = .087, partial η
2
 = .346.  An examination of the individual variables showed one significant 
result with regard to walking time, F (1,17) = 4.63, p = .046, partial η
2
 = .214.  In the cooled 
exercise condition, participants walked an average of 1257.13 feet (SD = 375.50) whereas in the 
uncooled exercise condition, participants walked an average of 1164.56 feet (SD = 302.81).  
While fatigue scores decreased in the cooled exercise condition (M = -6.28, SD = 17.40) from the 
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uncooled exercise condition (M = -1.39, SD = 14.84), this decrease in fatigue was not significant 
F (1,17) = 1.14, p = .300, partial η
2
 = .063.  The lack of significance was likely due to the large 
variance in fatigue scores in both conditions, but especially in the cooled exercise condition.  
There were no significant differences in exercise conditions with regard to percentage difference 
in walking time across the cooled exercise condition (M = .58, SD = .01) and uncooled exercise 
condition (M = .55, SD = .10), F (1,17) = 1.85, p = .192, partial η
2
 = .098. 
 
DEMOGRAPHICS AND SUBJECT CHARACTERISTICS 




EDSS Score, mean x ̅ 2.67, range 1.5-4 




FSS x ̅ 3.76, range 1.78-5.22 
MSIS x ̅ 61.67, range 34-83 
Taking Anti-fatigue Meds 2 
Taking Anti-spasticity Meds 2 
Assistive device 3 
Years since dx, mean (SD) x ̅ 20.5, range 4-35 years (+2.53) 















































N/A Betaseron N/A 








Baclofen N/A Walk aid 



















Tobias AFO, Cane 








N/A N/A N/A 


























Ampyra cane, orthotic 
Table 2: Subject Demographics & Characteristics 
MS, Multiple Sclerosis; EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; RR, relapsing-remitting; 
SP, secondary progressive; PP, primary progressive 
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 6 Minute Walk Test Cooled VAFS and 




















SUBJECT 1          
COOLED 1 -11   298.75 289.5 307.08 306.83 300.67 300 1802.83 
 2 -14 299.75 292.75 302.5 294.41 299.84 293.08 1782.33 
 3 20 333.83 331.63 334.04 332.16 333.5 330.17 1995.33 
SUBJECT 2          
COOLED 1 0 248.83 240 241.33 246.42 241.75 246.67 1465 
  2 0 249.83 241.83 243.25 245.92 241.17 226.41 1448.41 
  3 0 246.66 247.42 243 231.17 237.83 238.67 1444.75 
SUBJECT 3           
COOLED 1 20 174.08 182.33 196.5 183.09 178.75 192 1106.75 
  2 10 173.33 191.42 184.16 172.17 175.67 195.83 1092.58 
  3 9 175.41 198.67 191.83 190 190.75 188.92 1135.58 
SUBJECT 4          
COOLED 1 -46 168.3 200.53 200.42 200.41 212.09 201.66 1183.41 
 2 -20 174.08 199.17 207.58 201.83 221.42 219.58 1223.67 
 3 -36 180.83 214.83 220.84 221 221.25 221 1279.75 
SUBJECT 5          
COOLED 1 1 203.75 210.91 213.34 209.58 210.58 199.75 1247.91 
 2 0 197.33 202.17 203.58 210.83 204.09 190.08 1208.08 
 3 0 206.83 200.5 206.17 210.25 217.5 204.33 1245.58 
SUBJECT 6          
COOLED 1 -20 106.58 113.75 111.42 107.41 114.34 105.58 659.083 
 2 -11 100.83 104.08 97.09 103.75 103.66 105.17 614.58 





6 Minute Walk Test Uncooled VAFS and 















 5 (ft.) 
minute 
 6  (ft.) 
6 minute 
total (ft.) 
SUBJECT 1          
UNCOOLED 1 -4 255.75 263.71 256.62 260.92 257.91 271.5 1566.41 
 2 -6 255.08 243.58 254.17 251.92 247.91 249.34 1502 
 3 -5 248.16 256.17 253.17 250.16 243.84 247.58 1499.083 
SUBJECT 2          
UNCOOLED 1 1 232.416 233.084 221.91 221.25 212.75 209.17 1330.58 
  2 3 279 256.16 255.84 252.66 241.17 235.75 1520.58 
  3 -1 262.91 262.09 253.25 246.66 251.09 295.16 1571.16 
SUBJECT 3           
UNCOOLED 1 19 175.33 190.08 190.92 191.42 188.91 194.75 1131.4167 
  2 11 194.25 200 200.16 191.67 199.42 199.08 1184.58 
  3 21 181.91 178.67 175.25 174.75 167.33 167.34 1045.25 
SUBJECT 4          
UNCOOLED 1 7 142.83 158.5 165.33 168 171.42 174 980.08 
 2 -45 145.58 166.42 169.83 177.92 180.41 180.42 1020.58 
 3 13 128.75 155.08 156.75 160.17 160.1667 167.9133 928.83 
SUBJECT 5          
UNCOOLED 1 0 191.16 194.42 192.75 195 181.42 185.83 1140.58 
 2 0 192.83 213.92 213.83 233.08 225.34 208.58 1287.58 
 3 0 200.66 192.25 189.67 199.17 202.08 203.17 1187 
SUBJECT 6          
UNCOOLED 1 -13 113.83 126.58 117.42 114.25 107.83 101.42 681.33 
 2 -16 136.83 145.08 136.84 136.25 124.25 136.58 815.83 
 3 -10 100.25 107.91 96.25 87.75 90.17 86.83 569.16 
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In this study, we examined the effect of pericooling on gait endurance in persons with 
MS via the 6MWT.  We hypothesized that the use of a cooling garment would significantly 
improve gait endurance in our subjects.  Though various previous studies examined the effect of 
pre-cooling on gait (White et al., 2000, Nilsegard, Dension and Gunnarsson, 2006, Grahn, 
Murray and Heller, 2008 etc.), we specifically studied the use of pericooling, which may be more 
functional in therapy and daily living since it does not require extensive preparation before the 
activity is executed.  Our results indicated that our hypothesis was correct and that the 
application of a cooling vest during walking improved 6MWT scores compared to an uncooled 
condition.  Subjects walked significantly greater distances while wearing the vest and walked an 
average of 1257.12 feet compared to 1164.56 feet in the uncooled condition (p = .046).  The 
mean VAFS score decreased in both conditions as subjects reported less fatigue after performing 
the 6MWT.  The decrease in fatigue was greater in the cooled condition, though this difference 
was not statistically significant (p=.300).  Additionally, when comparing the percentage of 
distance covered each minute of the 6MWT, there was also no significant difference between the 
two conditions (p =. 192). 
MECHANISMS 
 MS is a chronic disease of the central nervous system, which involves axonal 
demyelination, inflammation, and oxidative stress (Romme Christensen et al., 2013). 
Demyelinating lesions in the central nervous system lead to the formation of scar tissue and 
cause changes in axonal physiology, decreased conduction velocity, and a predisposition for 
conduction blocks (Frohman et al., 2011).  While pwMS can exhibit a wide range of physical, 
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cognitive, and neurological symptoms, the most commonly experienced symptom is fatigue 
(Krupp et al. 1988) . 
For many pwMS, an increase in body temperature leads to worsening of symptoms.  This 
phenomenon, known as thermosensitivity, affects 60-80% of pwMS (Davis et al., 2010).  Heat 
can contribute to various impairments in pwMS, including increasing fatigue, decreasing 
strength, and increasing gait deviations (Geisler et al., 1996).  On a neuronal level, it has been 
suggested that heat contributes to conduction blocks by altering the propagation and the 
refractory period of the action potential (Smith, 1994).  Furthermore, pwMS often have deficits 
in thermoregulation, which can exacerbate this effect.    
It is possible that the use of a cooling vest increased ambulation endurance in our subjects 
by decreasing the effects of thermosensitivity.  Physical activity, such as walking, increases core 
temperatures.  The increase in temperature can lead to increased fatigue, decreased strength, and 
increased gait deviations limiting ambulation endurance. A cooling vest decreases body 
temperature, thereby ameliorating these effects.  
It is also possible that the cooled condition had a psychological impact on patients that 
contributed to their improved ambulation.  As Tyler and Sunderland (2011) concluded, the use of 
a cooling collar can decrease perceived exertion during exercise in healthy individuals. This 
suggests that cooling decreases perception of fatigue even in the general population.  
Additionally, in the MS population specifically, most pwMS are aware that heat makes their 
symptoms worse, and our subjects were aware that the vest was cold.  Their increased distance 
may have been in part due to the perception that they would perform better with the 
vest.  Similarly, simply wearing the vest, which was clearly the experimental condition, may 
have geared them to ambulate greater distances.  
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It is possible that the cooling vest also provided proprioceptive input which increased 
balance or motor control in the cooled subjects.  A study performed by DaCosta and McDonough 
demonstrated that a weighted vest decreased lateral sway during gait in children with sensory 
integration disorder (2005).  It is possible that the cooling vest used in our study, which weighed 
four pounds, also provided proprioceptive input that contributed to increased balance and gait 
improvements.  However, DaCosta and McDonough’s study involved children between the ages 
of five and 12 whose deficits were specifically related to processing sensory information, and 
therefore increased sensory input targeted these deficits.  It is unclear if a weighted vest would be 
helpful in a population such as ours in which the gait deficits are not due to a sensory integration 
disorder.  
The effect of using a weighted vest on gait in pwMS was examined in a 2014 study 
performed by Gorgas et al.  In this study, subjects were given selectively weighted vests, in 
which the weight was distributed based on the balance deficits of each subject.  The distribution 
of weight was determined based on an assessment of lateral sway with perturbations in each 
direction and was customized for each participant. Gorgas et al. found that wearing the weighted 
vest increased velocity, cadence, and time spent in single leg support in both pwMS and 
controls.  However, it is unclear if the vest that we used in our study, which was standardized 
and not individualized to the needs of each participant, would have a similar effect.  In fact, it is 
equally feasible that the vest used could have a negative impact on balance if the distribution of 
weight was not optimal for a specific subject. 
Though heat is known to increase fatigue in pwMS (Davis, Wilsons, White & Frohman, 
2010), the decrease in fatigue in the cooled condition was not statistically significant in this study 
(p=.300).  Fatigue is a subjective measure that cannot easily be quantified, and its origin is not 
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always definable.  In pwMS, fatigue can be due to demyelination and axonal loss characterized 
by the disease itself, or it can be induced by a variety of secondary factors.  These include 
difficulty sleeping, decreased activity levels, medication usage, depression, pain, and various 
other psychological factors (Kos, Kerckhofs, Nagels, D’Hooghe & Ilsroukx, 2008).  This study 
could not control for the variety of factors that may have influenced fatigue.  
Additionally, it is important to note that on average the patients in both conditions 
reported decreased fatigue after the 6MWT.  This suggests that the perception of fatigue was not 
the limiting factor that led to decreased ambulation endurance in the uncooled condition.  
However, it is important to note that the small sample size may have played a role in the reported 
decrease in fatigue across both conditions. Despite bootstrapping, the small n limits 
generalizability especially since fatigue is so subjective.  A larger sample size would provide 
more reliable data about the changes in fatigue during the 6MWT. 
The finding that there was no significant difference in the percentage of distance covered 
in each minute of the 6MWT across the two conditions may support the notion that fatigue was 
not the prime limiting factor in ambulation endurance.  If fatigue were the cause of decreased 
ambulation, we would have expected a consistent decline in distance covered in each progressive 
minute in the uncooled condition and more stable numbers in the cooled condition.  However, 
even in the uncooled condition, the percentages remained relatively stable throughout the 
duration of the walk for many of the subjects.  
Perhaps the decrease VAFS ratings with the 6MWT can be attributed to the 
psychological influences on fatigue.  As Noakes 2012 states “sensations of fatigue…. [are] 
largely independent of the real biological state of the athlete at the time they develop... 
Subconscious and conscious mental decisions made by winners and losers, in both training and 
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competition, are the ultimate determinants of both fatigue and athletic performance.” Motivation 
is an essential factor in fatigue perception. It is therefore possible that the excitement of 
accomplishing the six minute walk led to a decreased perception of fatigue with walking in both 
conditions as reflected by the VAFS. 
This discussion highlights the multifactorial nature of fatigue and therefore, the inherent 
difficulty in measuring fatigue in pwMS.  It is interesting to note that the EDSS scores of our 
subjects did not directly correlate with their FSIS scores, further emphasizing that the perception 
of fatigue is not a representation of true disability.  It is possible the 6MWT was not aggressive 
enough to induce a perceptible degree of fatigue in these subjects.  Some of the participants in 
the study walk for longer periods of time regularly and perhaps would require a greater duration 
of ambulation before the onset of fatigue.  Interestingly, the only subject with a consistent 
increase in fatigue throughout trials also had a significantly higher EDSS score than the other 
subjects, reflecting that the increase in perceived fatigue with the 6MWT correlates with 
decreased baseline walking ability.    
Though fatigue was not perceived to increase, the decrease in mean walking distance in 
the uncooled condition suggests that on some level fatigue did interfere with their walking 
ability.  However the subjective, multifactorial nature of fatigue limits our ability to quantify its 
effect on walking performance.  It is also possible that the other symptoms associated with 
thermosensitivity, such as spasticity and gait deviations, were the main cause for the decrease in 
ambulation distance rather than fatigue perception.  Cooling, which prevents the onset of 






There were a number of limitations observed during this study.  MS is widely variable in 
its presentation, including symptom severity and frequency, age of onset, and affected areas of 
the body.  Additionally, there is variability in the patients’ ability to cope psychologically with 
their disease.  Though our study represented a wide range of MS presentations, a larger sample 
size is needed to get a true sense of how cooling impacts pwMS as a whole, and therefore the 
small sample size (six) limits the generalizability of this study.  It is possible, for instance that 
the decrease in fatigue with the 6MWT was due to specific characteristics of the individuals 
studied, and that in a larger sample, the results would be different.  Though the diversity of our 
subjects adds to the generalizability of our results, a larger sample size is needed to obtain a more 
accurate understanding of the effect of a cooling vest on pwMS. 
Another limitation of this study was the possibility of a phenomenon called Hawthorne 
Effect, whereby subjects of an experiment alter their behavior when they know they are being 
examined, often in an effort to please the examiner or provide what they feel are the correct 
results.  Participants were patients of the faculty advisor for this research project and may have 
discussed with him the effects of cooling on pwMS during their therapy sessions in the 
past.  Since he is a significant facilitator and advocate in their health and well-being, these 
discussions could have influenced their performance based on an awareness of his hypothesis. 
Reporting and assessment of fatigue on a VAFS is subjective and susceptible to varied 
interpretation by the participants.  Thresholds differ between subjects.  What some subjects 
consider exhaustion, others view as mildly low energy, suggesting that personality and 
sensitivity may impact reporting of fatigue levels.  There is also the possibility that these 
interpretations can change from day to day depending on the variable presentation of 
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psychological and physical symptoms with MS.  A study performed by Flachenecker et al. in 
2002 examined multiple scales used to measure fatigue in MS and found a poor correlation 
between the scales due to the multifactorial nature of fatigue.  The study found that depression 
scores were highly correlated with fatigue since MS patients with depression showed 
significantly higher FSS scores than those without. Additionally, the feeling of accomplishment 
from having completed a task of importance (in this case, a research trial) may have diverted 
attention from or even mitigated awareness of fatigue.  This variability in the perception and 
reporting of fatigue makes it a very difficult measure to collect with baseline consistency from 
one trial to the next.  Perhaps a quantifiable measure, such as change in body temperature, would 
be beneficial to compare with the acquired measurement of distance walked since it eliminates 
the process of participant interpretation. 
Scheduling also posed a possible limitation to this study.  Due to work and family 
obligations, time of day that testing occurred differed among subjects, some of whom could only 
come early in the morning, while others could only come later in the day or early 
evening.  Therefore, while some subjects were tested after a full night’s sleep, others may have 
experienced a day of substantial activity prior to testing.  However, testing times were consistent 
with each individual, and therefore level of fatigue due to previous activity was relatively 
consistent.  Additionally, due to scheduling conflicts intervals between testing ranged from one-
two weeks.   
Outdoor and testing environment temperature also contributed to the limitations of this 
study.  Even though all subjects underwent a 15 minute rest period before each walking trial, 
there was variability in both weather and building temperature from week to week, often, but not 
always, with an inverse relationship whereby colder outdoor temperatures yielded warmer indoor 
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temperatures and vice versa.  These direct environmental influences might have had an effect on 
body temperature, varying the baseline from which cooling with the vest began. 
The vest had multiple characteristics other than temperature, which makes it difficult to 
isolate the effect of cooling on gait.  The cooling vest used in this study, constructed out of 
canvas, had nine pockets into which ice packs were placed during cooling trials.  The weight of 
the vest, though reported by all subjects to cause no discomfort or adverse response, presents a 
limitation to the study as the trial that incorporated pericooling required an additional, though 
nominal, load to the subjects.  Conversely, the vest may have provided proprioceptive and 
psychological benefits to its wearers, resulting in improved walking performance during 
pericooling trials.  Though this limits our ability to isolate the effect of cooling on gait, it 
provides more information on the practical uses of the vest in the therapeutic context. 
During the course of the study, there were two reported injuries due to falls outside of the 
testing trials, which may have impacted walking performance.  When questioned by the 
researchers, however, the two subjects who had sustained the falls contended that they were able 
to carry out the trial with no difficulty as a consequence of their injuries. 
Recording the feet walked at each minute of the 6MWT was subject to human 
error.  Measurement was performed by following the walking path of the subject with a hand-
held wheel and recording how many feet the subject walked each minute.  While the path was 
linear and pre-planned with few direction changes, the trajectory of the wheel was prone to slight 
lateral curving during its course.  Possible measurement errors may have contributed to a small 
amount of variation in the collected results. 
Another possible limitation of the study was that some subjects engaged in conversation 
with their walk test administrators during trials, while other subjects kept discussion to a 
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minimum for the duration of the walk test.  Since certain individuals are more naturally social, it 
is unclear whether or not this difference in behavior had an affect on their walking 
performance.  While it may have distracted or placed unnecessary demands on the subject, thus 
impeding performance, it may just as likely have put the subject at ease and improved 
performance.  To further eliminate external influence on performance, future testing might 
encourage minimal or no conversation during the walk trial to encourage focus on the physical 
task at hand.  Conversely, the purpose of this study was to observe the effects of pericooling on 
walking, and conversation with walking is customary and often necessary. 
FUTURE STUDIES 
In addition to increasing the sample size and regulating more factors during testing trials 
such as time of day and weather, there are several considerations that might be addressed with 
future studies.  This same study could be conducted in which a cooled condition is compared to a 
sham cooling.  Sham cooling is a process in which subjects in the uncooled group wear vests that 
provide a significantly lower level of cooling to evoke the perception of being cooled without the 
associated physiological effects.  This would distinguish between the physiological and 
psychological effects of cooling..  Likewise, to eliminate the extra weight of the cooling garment, 
the walk test might be conducted in a corridor cooled to a specific and regulated 
temperature.  Additionally, all subjects may be required to wear the same outfits so that they 
have an equivalent layer of insulation between their skin and the external temperature imposed 
on them.  To further quantify the subjects’ baseline and thermosensitivity, testers may consider 
taking measurements of body or skin temperature to determine how affected each subject is by 
the cooling process.  Future studies can also compare precooling to pericooling to see if there is 
any benefit to precooling over the more functional pericooling. 
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Another consideration for testing the effects of cooling during gait might be to calculate 
the number of steps taken during the 6MWT in addition to distance travelled.  This measurement 
takes into account individual stride lengths based on height and functional ability, and therefore, 
provides a quantifiable and more individual report of walking response in both cooled and 
uncooled trials.  Additionally, future studies could explore the changes in gait kinematics with a 
cooling vest to determine more precisely the mechanism by which cooling increases the 
ambulation distance.  Future studies could also explore the effect of cooling on other functional 
measures, such as balance and coordination, and could examine the effect of cooling on longer 
distance ambulation, which may be more likely to induce perceptible fatigue in ambulatory 
individuals with MS. 
CLINICAL SIGNIFICANCE 
Pericooling is a time conserving approach in comparison to precooling.  Pericooling does 
not require individuals to arrange their schedules in order to set aside time to precool before 
performing physical activity. Rather, pericooling allows the individual to don the vest just as 
they are beginning the activity.  As it is, many individuals with MS report that performing basic 
ADLs is extremely time consuming and that they do not have the extra time to pre-cool as it 
would make a simple task, such as going to a supermarket, a full day excursion.  Pericooling can 
be a very practical means by which pwMS can increase their productivity and maintain a more 
active and functional lifestyle without requiring them to set aside time to precool.  Additionally, 
the individual can spontaneously decide to participate in an activity without extensive 
preparation.  
The use of a cooling vest for pericooling can also have practical implications during 
physical therapy sessions as it can effectively manage heat related symptoms and allow the 
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individual to ambulate more functional distances.  This will allow physical therapy sessions to be 
more productive since it doesn’t require the individual to don the vest prior to the session, a task 
that can be very time consuming and require the individual to arrive earlier. 
Cooling vests are a very practical means of decreasing core temperature and lessening the 
effects of thermosensitivity.  The vests contain multiple insulated pockets that hold the ice packs. 
They are lightweight (four pounds) and can be worn over  clothing to provide cooling relief that 
can last up to a few hours.  Individuals can order multiple sets of ice packs, which can be stored 
in the freezer for use at any time.  Furthermore, the vests are extremely affordable, and many 
programs, such as the MSAA Cooling program, offer the vests free of charge for pwMS.  
 
CONCLUSION 
Many individuals with MS are heat sensitive and experience fatigue when their core 
temperature rises with exercise. This affects their ability to ambulate functional distances.  Our 
results show that the use of a cooling vest during ambulation has positive effects on ambulation 
distance.  This can have important implications for ameliorating the effects of thermosensitivity 
and improving exercise tolerance.  The use of a cooling vest is a convenient and affordable 
intervention that does not require extensive preparation and can therefore be a practical 
intervention.  Future studies are necessary to ascertain if there is any advantage to precooling 









APPENDIX A: RECRUITMENT FLIER 
Do you want to contribute to  
MS research? 
 
Volunteers needed for a study to determine the effect 
of using a cooling vest on gait endurance in persons 
with Multiple Sclerosis. 
 
Participant requirements: 
 Must be able to walk for 6 minutes unassisted with or 
without an assistive device 
 Must have had no exacerbations within the last 3 months. 
 Must not be currently taking steroidal medication.  
 Must be available January-April 2014. 
 
Study to be conducted at: 
Hunter College Brookdale Health Science Campus 
425 East 25th Street New York, NY 10010 
*Travel expenses will be reimbursed. 
 
If interested, contact: 
Herb Karpatkin, PT, Dsc 




APPENDIX B: CONSENT TO PARTICIPATE IN A SCREENING PROCESS  
 
Hunter College  
Program in Physical Therapy 
City University of New York 
 




Herbert I. Karpatkin, PT, DSc.  
Esther Sosowsky, SPT 
Meghan Higgins, SPT 
Elisheva Zinberg, SPT 
Hunter College, Program in Physical Therapy 
City University of New York 
212-481-5051 
 
Purpose and Background 
Dr. Herbert Karpatkin, PT DSc is a professor at Hunter College in the Physical Therapy 
Department.  Esther Sosowsky, Meghan Higgins, and Elisheva Zinberg are doctoral students in 
the Physical Therapy Program at Hunter College.   They are conducting a study examining the 
effects of cooling on gait endurance in persons with multiple sclerosis (MS).  You are being 
asked to participate in the screening process to determine eligibility for this study that will help 
determine if wearing a cooling garment while walking allows persons with MS to walk longer 
distances. You were selected for participation because you are a person with MS over 18 years of 
age who walks as a regular means of transportation.  There will be an anticipated 15 subjects that 
will participate in this screening process. Your participation in the screening process is voluntary.  
You may choose to not participate from the start and you may choose to stop at any time during 
the process.   
 
Procedures 
On the first day, you will fill out a demographics questionnaire in Hunter College, after which 
you will be interviewed by researchers to address any necessary follow up questions in order to 
determine if you are eligible for the study.   All subsequent sessions will also take place at the 
Physical Therapy Department of Hunter College, at 425 east 25
th
 street, basement level.   
 
 The screening process will involve answering questions about your medical history 
including length of time with MS, medications, use of assistive devices for walking such 
as canes, walkers, or splints, and whether you have a history of non-MS complications 
such as a cardiac condition or orthopedic problems. The researchers will also look at 
information from your medical records such as your Expanded Disability Scale Score 
(EDSS) and MS Quality of Life score (MS QOL-54). 




 If you are not eligible to participate, the information obtained from you during the 
screening process will be omitted from this study and shredded to protect your privacy.  
 
None of the procedures or questionnaires in this study is experimental. The only experimental 
aspect of this study is the gathering of information for the purpose of analysis. 
 
Risks 
There are minimal risks to you for participating in the screening process of this study.  The 
screening process will require a maximum of 15 minutes of your time.  Confidentiality of the 
information will be safeguarded by de-identifying subjects and filing any identifying information 
in a locked cabinet located at Dr. Karpatkin’s private practice.  All identifying information will 
be destroyed at the conclusion of the study.  If deemed inelligable, or if at any time you choose 
not to participate, data will be destroyed.  You have the choice to refuse to answer any item in 
any of the questionnaires or forms. 
 
Benefits 
There are no direct benefits to you resulting from the screening process.  
 
Alternatives 
The alternative to this study is nonparticipation without repercussions or penalties.  
 
Financial Considerations 
Other than the cost of travel to and from the Hunter College Brookdale Campus, there are no 
costs incurred by you for participation in the screening process.   
 
Confidentiality 
Strict confidentiality will be maintained.  Knowledge of your identity and participation in the 
screening process will be limited to Dr. Karpatkin, the collaborating physical therapy students, 
and IRB members and staff.  Information about your participation will only be disclosed in the 
event of an emergency requiring hospitalization, and in such a case will be disclosed to the 
treating hospital physician and your primary care physician.  Under expected non-emergency 
circumstances, no individual identifying information about you will be disclosed.  Where 
possible, all identifying references about you will be removed and replaced by a numeric code. 
Participation in this research is voluntary and involves minimal loss of your privacy.  All 
questionnaires and data about you that will be used in computer analysis will have number codes 
rather than your name. Your name will not be recorded on the information or reported in any 
scientific paper or professional meeting to protect your identity.  All data will be reported in 
aggregate (group) fashion at a professional meeting or in a scientific journal so that no one can 
identify any information about you.  If data is used for a publication in the medical literature or 
for teaching purposes, no names will be used. A master list of code numbers as well as all other 
data pertaining to you and other subjects will be kept confidential by the researchers and will be 
stored in a locked file cabinet in the faculty research advisor’s office.  Data that will be used for 
computer analysis will be kept on a flash drive and only researchers involved in this study and 
IRB members and staff will have access to the records and information about this study. All 
original hardcopy data will be shredded seven years after completion of the study. The code key 
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connecting names to numbers will be kept in the research office of Dr. Karpatkin. Confidentiality 
will be maintained to the extent allowed by law. 
 
Withdrawal 
You may terminate your participation from the screening process prior to the start or at any time 
during the process without penalty or repercussion. 
 
Contact Information  
If you have questions about the screening process, you can contact Dr. Karpatkin, at (212) 481-
5051.  You should contact the Hunter College Human Research Protection Program (HRPP) 
Office at hrpp@hunter.cuny.edu or 212-650-3053, if you have questions regarding your rights as 
a subject or if you feel you have been harmed as a result of your participation in this research. 
 
Signatures  
I have read (or have had read to me) the contents of this consent form and have been encouraged 
to ask questions.  I have received answers to my questions.  I give my consent to participate in 
the screening process to determine if I am eligible to participate in the research study.  I have 




______________________  ___________________________  ___________ 




______________________  ___________________________  ___________ 




APPENDIX C: CONSENT TO PARTICIPATE AS A RESEARCH SUBJECT  
 
Hunter College  
Program in Physical Therapy 
City University of New York 
 




Herbert I. Karpatkin, PT, DSc.  
Esther Sosowsky, SPT 
Meghan Higgins, SPT 
Elisheva Zinberg, SPT 
Hunter College, Program in Physical Therapy 
City University of New York 
425 E 25th St 
New York, NY 10010 
212-481-5051 
 
Purpose and Background 
Dr. Herbert Karpatkin, PT DSc is a professor at Hunter College in the Physical Therapy 
Department.  Esther Sosowsky, Meghan Higgins and Elisheva Zinberg are doctoral students in 
the Physical Therapy Program at Hunter College.   They are conducting a research study 
examining the effects of wearing a cooling vest on gait endurance in persons with Multiple 
Sclerosis (MS).  You are being asked to participate in a research study that will help determine if 
wearing a cooling garment during ambulation allows persons with MS to walk longer distances. 
You were selected for participation because you are a person with MS over 18 years of age who 
walks as a regular means of getting around/commuting.  There will be an anticipated 15 subjects 
that will participate in this research study. Your participation in this study is voluntary.  You may 
choose to not participate from the start and you may choose to stop at any time during the study.   
 
Procedures 
All sessions will take place at the Physical Therapy Department of Hunter College, at 425 east 
25
th
 street, basement level.  On the first day, you will fill out a demographics questionnaire as 
well as a simple fatigue survey and a quality of life scale. You will then be randomly assigned 
into a cooled or uncooled group, and will receive the corresponding vest (with or without cooling 
capabilities, depending on the group). Wearing the vest, you will perform a timed walking trial, 
and then fill out a quick fatigue survey.  Each session will last approximately 45 minutes on two 
occasions per week for 3 weeks followed by 2 weeks without intervention. You will then repeat 
this protocol wearing the other kind of vest, for 3 more weeks.    
 
The study procedures in detail are as follows: 
 If you agree to participate in the study, you will complete a questionnaire in Hunter 
College with the researchers to determine if you are eligible for the study. The screening 
will ask questions about your medical history including length of time with MS, 
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medications, use of assistive devices for walking such as canes, walkers, or splints, and 
whether you have a history of non-MS complications such as a cardiac condition or 
orthopedic problems. The researchers will also look at information from your medical 
records such as your Expanded Disability Status Scale Score (EDSS) and MS Quality of 
Life score (MS QOL-54). 
 If your responses indicate that you are eligible, you will be asked to participate in this 
study.  
 If you are not eligible to participate, the information obtained from you during screening 
will be removed from this study and destroyed/shredded to protect your privacy.  
 If you are chosen to continue, you will complete one form that will inquire about your 
level of fatigue, and another that will inquire about the physical and psychological 
impact of MS on your life. 
 You will then be randomly assigned to one of two groups: cooled or uncooled. 
 You will receive one of two vests, depending on your assigned group, with or without 
cooling capabilities. 
 After a fifteen minutes seated rest period, you will be asked to perform a single 6-minute 
continuous walk. The walk should be performed at your best comfortable pace. You will 
be guarded by Dr. Karpatkin for the entire walk.  You will also be followed with a 
wheelchair by one of the collaborating physical therapy students for the entire walk. 
Immediately after completing the walk, you will fill out a fatigue form that asks about 
your level of fatigue at that moment. The distance that you walk will be recorded every 
minute.  You will be asked to perform this timed walk twice a week for the initial 3-week 
period. 
  Following the initial 3-week period, there will be a 2-week detraining period, during 
which no walking intervention will take place. 
 After the 2-week detraining period, you will return and perform the 6-minute walk 
wearing the vest that you did not wear during the first 3-week session. If you wore a 
cooled vest during the first 3 weeks, you will be asked to perform the walk wearing an 
uncooled vest during the second 3-week training period. If you wore an uncooled vest 
during the first 3 weeks, you will wear a cooled vest during the second 4-week training 
period. As with the first 3-week period, immediately before and after the timed walk, 
you will complete the form related to your current level of fatigue. Distances will be 
measured in the same manner as previously. You will be free not to answer any item in 
any of the questionnaires or forms. 
 At each visit, please bring with you any walking devices such as canes, walkers, splints 
etc. that you would normally use for walking. Please bring the same comfortable 
walking shoes to all sessions.  
 The total time expected for each session is 45 minutes.  
 
 
None of the procedures or questionnaires in this study is experimental. The only experimental 
aspect of this study is the gathering of information for the purpose of analysis. 
 
Risks and/or Discomfort 
There are minimal risks to you from participation in this study. You may experience some 
fatigue-related discomfort as a result the walking protocol. Because fatigue is the most common 
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symptom in persons with MS, it is important to note that any fatigue experienced may be 
characteristic of the disease itself, as opposed to a result of the testing conditions. The walking 
protocol of this study is not expected to worsen your fatigue, or any other aspect of your MS in 
any way. Dr. Karpatkin will walk beside you for the entire walk. You will also be followed by 
one of the physical therapy students with a wheelchair. Despite these safeguards, there is a 
chance that you could incur an orthopedic injury from the walking or that you may fall and get 
injured.  If this should occur we will immediately contact your primary care physician and if 
necessary take you to the emergency room.  
 
If you feel bothered or upset as a result of participation, or for any reason wish to not continue 
you may simply ask to stop and we will immediately end the procedure. You will be free not to 
answer any item in any of the questionnaires or forms. 
 
Benefits 
There may be no direct benefits to you as an individual. You may experience an increase 
awareness of your fatigue levels, and how they may vary based on the use of a cooling garment.  
 
Alternatives 
The alternative to this study is not to participate, without repercussions or penalties.  
 
Voluntary Participation: Your participation in this study is voluntary, and you may decide not 
to participate without prejudice, penalty, or loss of benefits to which you are otherwise entitled.  
If you decide to leave the study, please contact the principal investigator Esther Sosowsky, SPT 
at (718)-483-0621 or via email es125@hunter.cuny.edu to inform her of your decision.   
 
Financial Considerations 
Other than the cost of travel to and from the Hunter College Brookdale Campus, there will be no 
costs incurred by you for participation in the study. You will receive an $80.00 MetroCard to 
cover your travel-related expenses.  This money does not obligate you to continue the study if at 
any point you wish to stop. You may terminate your participation at any time and you will still 
receive this compensation.  
 
Confidentiality 
The data will be collected using the two fatigue surveys that you fill out and by measuring the 
distance walked within each timed walk.  Strict confidentiality will be maintained.  Knowledge 
of your identity and participation in this study will be limited to Dr. Karpatkin, the collaborating 
physical therapy students, and the IRB members and staff.  Information about your participation 
will only be disclosed in the event of an emergency requiring hospitalization, and in such a case 
will be disclosed to the treating hospital physician and your primary care physician.  Under 
expected non-emergency circumstances, no individual identifying information about you will be 
disclosed.  Where possible, all identifying references about you will be removed and replaced by 
a numeric code. Participation in this research is voluntary and involves minimal loss of your 
privacy. All questionnaires and data about you that will be used in computer analysis will have 
number codes rather than your name. Your name will not be recorded on the information or 
reported in any scientific paper or professional meeting to protect your identity. All data will be 
reported in aggregate (group) fashion at a professional meeting or in a scientific journal so that 
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no one can identify any information about you. If data are used for a publication in the medical 
literature or for teaching purposes, no names will be used. A master list of code numbers as well 
as all other data pertaining to you and other subjects will be kept confidential by the researchers 
and will be stored in a locked file cabinet in the faculty research advisor’s office.  Data that will 
be used for computer analysis will be kept on a flash drive and only researchers involved in this 
study and IRB members and staff will have access to the records and information about this 
study. All original hardcopy data will be shredded seven years after completion of the study. The 
code key connecting names to numbers will be kept in the research office of Dr. Karpatkin. 
Confidentiality will be maintained to the extent allowed by law. 
 
Withdrawal 
You may terminate your participation from this study prior to the start or at any time during the 
study without penalty, repercussion, or loss of compensation. 
 
Contact Information  
If you have questions about the study, you can contact Dr. Karpatkin, at (212) 481-5051.  You 
should contact the Hunter College Human Research Protection Program (HRPP) Office at 
hrpp@hunter.cuny.edu or 212-650-3053, if you have questions regarding your rights as a subject or 
if you feel you have been harmed as a result of your participation in this research. 
 
Signatures  
I have read (or have had read to me) the contents of this consent forms and have been 
encouraged to ask questions.  I have received answers to my questions.  I have received answers 
to my questions. I give my consent to participate in this study.  I have received (or will receive) a 




______________________  ___________________________  ___________ 




______________________  ___________________________  ___________ 









Do you have a definitive diagnosis of MS? 
  Yes    No 
Are you able to understand and sign informed consent? 
    Yes    No 
 
Can you ambulate continuously for six minutes with or without an assistive device? 
  Yes    No 
 
Do you have any type of orthopedic or cardiopulmonary condition preventing your ability to walk six 
minutes? 
  Yes    No 
 
Have you had a recent exacerbation of your symptoms? 
  Yes    No 
 
Have you taken steroidal medication within the past 4 weeks? 
   Yes    No 
 
 
Subject Demographic Information 
 
Age: __________           Gender: M  /  F     Date of Birth: __________________ 
Type of Multiple Sclerosis:  _______________________________________________________ 
Year since diagnosis of Multiple Sclerosis:  __________________________________________ 
Expanded disability status scale (EDSS) Score: ____________________ 
Fatigue Severity Scale (FSS) Score:  ____________________ 
MSIS Score:  ____________________ 
Use of assistive device: __________________________________________________________ 
Use of anti-spasticity medications:  _________________________________________________ 
Use of fatigue medication:  _______________________________________________________ 
Use of any other medication: ______________________________________________________ 




APPENDIX E: FATIGUE SEVERITY SCALE (FSS)  
 
 
Fatigue Severity Scale (FSS) 
 
Your Name             
 




This questionnaire contains nine statements that rate the severity of your fatigue symptoms.  
Read each statement and circle a number from 1 to 7, based on how accurately it reflects your 
condition during the past week and the extent to which you agree or disagree that the statement 
applies to you. 
 
***A low value (e.g. 1) indicates strong disagreement with the statement, whereas a high value 
(e.g. 7) indicates strong agreement. 
 
During the past week, I have found that:                 Disagree             Agree 
 
1. My motivation is lower when I am fatigued        1   2   3   4   5   6   7       
 
2. Exercise brings on my fatigue.       1   2   3   4   5   6   7       
 
3. I am easily fatigued.        1   2   3   4   5   6   7       
 
4. Fatigue interferes with my physical functioning.     1   2   3   4   5   6   7       
 
5. Fatigue causes frequent problems for me.      1   2   3   4   5   6   7       
 
6. My fatigue prevents sustained physical functioning.    1   2   3   4   5   6   7       
 
7. Fatigue interferes with carrying out certain duties and responsibilities.  1   2   3   4   5   6   7          
 
8. Fatigue is among my three most disabling symptoms.    1   2   3   4   5   6   7          
 
9. Fatigue interferes with my work, family or social life.    1   2   3   4   5   6   7          
 
 
          Total Score:     
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APPENDIX F: MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) 
 





 For each statement, please circle the one number that best describes your situation  
 
 Please answer all questions  
 
 
In the past two weeks, how much has your 










1. Do physically demanding tasks? 
 
1 2 3 4 5 
2. Grip things tightly (e.g. turning on 
taps)? 
1 2 3 4 5 
3. Carry things? 
 
1 2 3 4 5 
 
In the past two weeks, how much have you 










4. Problems with your balance? 
 
1 2 3 4 5 
5. Difficulties moving about indoors? 1 2 3 4 5 
6. Being clumsy? 
 
1 2 3 4 5 
7. Stiffness? 
 
1 2 3 4 5 
8. Heavy arms and/or legs? 
 
1 2 3 4 5 
9. Tremor of your arms or legs? 
 
1 2 3 4 5 
10. Spasms in your limbs? 
 
1 2 3 4 5 
11. Your body not doing what you want it 
to do? 
1 2 3 4 5 
12. Having to depend on others to do 
things for you? 
1 2 3 4 5 
 
 
Please check that you have answered all the questions before going on to the next page 
®2000 Neurological Outcome Measures Unit, 4
th
 Floor Queen Mary Wing, NHNN, Queen 





In the past two weeks, how much have you 










13. Limitations in your social and leisure 
activities at home? 
1 2 3 4 5 
14. Being stuck at home more than you 
would like to be? 
1 2 3 4 5 
15. Difficulties using your hands in everyday 
tasks? 
1 2 3 4 5 
16. Having to cut down the amount of time 
you spent on work or other daily 
activities? 
1 2 3 4 5 
17. Problems using transport (e.g. car, bus, 
train, taxi, etc.)? 
1 2 3 4 5 
18. Taking longer to do things? 
 
1 2 3 4 5 
19. Difficulty doing things spontaneously (e.g. 
going out on the spur of the moment)? 
1 2 3 4 5 
20. Needing to go to the toilet urgently? 1 2 3 4 5 
21. Feeling unwell? 
 
1 2 3 4 5 
22. Problems sleeping? 
 
1 2 3 4 5 
23. Feeling mentally fatigued? 
 
1 2 3 4 5 
24. Worries related to your MS? 
 
1 2 3 4 5 
25. Feeling anxious or tense? 
 
1 2 3 4 5 
26. Feeling irritable, impatient, or short 
tempered? 
1 2 3 4 5 
27. Problems concentrating? 
 
1 2 3 4 5 
28 Lack of confidence? 
 
1 2 3 4 5 
29. Feeling depressed? 
 
1 2 3 4 5 
 
 
Please check that you have circled ONE number for EACH question 
 2000 Neurological Outcome Measures Unit, 4th Floor Queen Mary Wing, NHNN, Queen 



















APPENDIX H: VISUAL ANALOG FATIGUE SCALE 
 
Visual Analog Fatigue Scale 
 
 










(mm) Min 1 (ft.) 
 
Min 2 (ft.) Min 3 (ft.) Min 4  (ft.) Min 5  (ft.) Min 6 (ft.) TOTAL (ft.) 
Cooled    
 
     
 TRIAL 1         
 TRIAL 2         
 TRIAL 3         
Uncooled    
 
     
 TRIAL 1         
 TRIAL 2         
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